These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

272 related items for PubMed ID: 28303266

  • 41. Development and biological investigations of hypoxia-sensitive prodrugs of the tyrosine kinase inhibitor crizotinib.
    Bielec B, Schueffl H, Terenzi A, Berger W, Heffeter P, Keppler BK, Kowol CR.
    Bioorg Chem; 2020 Jun; 99():103778. PubMed ID: 32229347
    [Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43. Glucose conjugated platinum(II) complex: antitumor superiority to oxaliplatin, combination effect and mechanism of action.
    Li H, Gao X, Liu R, Wang Y, Zhang M, Fu Z, Mi Y, Wang Y, Yao Z, Gao Q.
    Eur J Med Chem; 2015 Aug 28; 101():400-8. PubMed ID: 26177447
    [Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Targeting Energy Metabolism by a Platinum(IV) Prodrug as an Alternative Pathway for Cancer Suppression.
    Jin S, Guo Y, Song D, Zhu Z, Zhang Z, Sun Y, Yang T, Guo Z, Wang X.
    Inorg Chem; 2019 May 06; 58(9):6507-6516. PubMed ID: 31013065
    [Abstract] [Full Text] [Related]

  • 46. A platinum(iv) prodrug to defeat breast cancer through disrupting vasculature and inhibiting metastasis.
    Guo Y, Zhang S, Yuan H, Song D, Jin S, Guo Z, Wang X.
    Dalton Trans; 2019 Mar 12; 48(11):3571-3575. PubMed ID: 30793153
    [Abstract] [Full Text] [Related]

  • 47. Functional fluorescent nonporous silica nanoparticles as carriers for Pt(IV) anticancer prodrugs.
    Ravera M, Perin E, Gabano E, Zanellato I, Panzarasa G, Sparnacci K, Laus M, Osella D.
    J Inorg Biochem; 2015 Oct 12; 151():132-42. PubMed ID: 26277416
    [Abstract] [Full Text] [Related]

  • 48. Multimodal targeting of tumor vasculature and cancer stem-like cells in sarcomas with VEGF-A inhibition, HIF-1α inhibition, and hypoxia-activated chemotherapy.
    Yoon C, Chang KK, Lee JH, Tap WD, Hart CP, Simon MC, Yoon SS.
    Oncotarget; 2016 Jul 12; 7(28):42844-42858. PubMed ID: 27374091
    [Abstract] [Full Text] [Related]

  • 49. Multifunctional Pt(iv) prodrug candidates featuring the carboplatin core and deferoxamine.
    Harringer S, Hejl M, Enyedy ÉA, Jakupec MA, Galanski MS, Keppler BK, Dyson PJ, Varbanov HP.
    Dalton Trans; 2021 Jun 21; 50(23):8167-8178. PubMed ID: 34031671
    [Abstract] [Full Text] [Related]

  • 50. Design, synthesis, and evaluation of benzofuran derivatives as novel anti-pancreatic carcinoma agents via interfering the hypoxia environment by targeting HIF-1α pathway.
    Xu XL, Yang YR, Mo XF, Wei JL, Zhang XJ, You QD.
    Eur J Med Chem; 2017 Sep 08; 137():45-62. PubMed ID: 28554092
    [Abstract] [Full Text] [Related]

  • 51. DMAKO-20 as a New Multitarget Anticancer Prodrug Activated by the Tumor Specific CYP1B1 Enzyme.
    Cui J, Zhang X, Huang G, Zhang Q, Dong J, Sun G, Meng Q, Li S.
    Mol Pharm; 2019 Jan 07; 16(1):409-421. PubMed ID: 30481041
    [Abstract] [Full Text] [Related]

  • 52. Synthesis and biological studies of the thiols-triggered anticancer prodrug for a more effective cancer therapy.
    Xu Y, Chen J, Li Y, Peng S, Gu X, Sun M, Gao K, Fang J.
    Org Biomol Chem; 2015 Mar 07; 13(9):2634-9. PubMed ID: 25581090
    [Abstract] [Full Text] [Related]

  • 53. Functionalized nonporous silica nanoparticles as carriers for Pt(iv) anticancer prodrugs.
    Ravera M, Gabano E, Zanellato I, Perin E, Arrais A, Osella D.
    Dalton Trans; 2016 Nov 01; 45(43):17233-17240. PubMed ID: 27722707
    [Abstract] [Full Text] [Related]

  • 54. Design, synthesis of novel celastrol derivatives and study on their antitumor growth through HIF-1α pathway.
    Shang FF, Wang JY, Xu Q, Deng H, Guo HY, Jin X, Li X, Shen QK, Quan ZS.
    Eur J Med Chem; 2021 Aug 05; 220():113474. PubMed ID: 33930802
    [Abstract] [Full Text] [Related]

  • 55. Solution-phase synthesis and biological evaluation of triostin A and its analogues.
    Hattori K, Koike K, Okuda K, Hirayama T, Ebihara M, Takenaka M, Nagasawa H.
    Org Biomol Chem; 2016 Feb 14; 14(6):2090-111. PubMed ID: 26779679
    [Abstract] [Full Text] [Related]

  • 56. Ring-truncated deguelin derivatives as potent Hypoxia Inducible Factor-1α (HIF-1α) inhibitors.
    Kim HS, Hong M, Lee SC, Lee HY, Suh YG, Oh DC, Seo JH, Choi H, Kim JY, Kim KW, Kim JH, Kim J, Kim YM, Park SJ, Park HJ, Lee J.
    Eur J Med Chem; 2015 Nov 02; 104():157-64. PubMed ID: 26457742
    [Abstract] [Full Text] [Related]

  • 57. Kamebakaurin inhibits the expression of hypoxia-inducible factor-1α and its target genes to confer antitumor activity.
    Wang KS, Ma J, Mi C, Li J, Lee JJ, Jin X.
    Oncol Rep; 2016 Apr 02; 35(4):2045-52. PubMed ID: 26781327
    [Abstract] [Full Text] [Related]

  • 58. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
    Payne JE, Bonnefous C, Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL, Hoffman TZ, Rao TS, Shiau AK, Malecha JW, Noble SA, Hager JH, Smith ND.
    Bioorg Med Chem Lett; 2008 Dec 01; 18(23):6093-6. PubMed ID: 18954983
    [Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60. Discovery of P3971 an orally efficacious novel anticancer agent targeting HIF-1α and STAT3 pathways.
    Godse P, Kumar P, Yewalkar N, Deore V, Lohar M, Mundada R, Padgaonkar A, Manohar S, Joshi A, Bhatia D, Desai N, Damre A, Bhonde M, Joshi K, Sharma R, Kumar S.
    Anticancer Agents Med Chem; 2013 Nov 01; 13(9):1460-6. PubMed ID: 24102269
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.